The present disclosure relates to tissue engineering, and more particularly to a method for treating or repairing rotator cuff or other tendon tears or damage using scaffold-free, 3-dimensional engineered tendon constructs.

CRISPR/Cas9-mediated genome editing holds clinical potential for treating genetic diseases, such as Duchenne muscular dystrophy (DMD), which is caused by mutations in the dystrophin gene. Here, using three promoters to drive expression of the same DMD guide RNA, a more robust and safe form of genome editing was achieved in a humanized mouse model for DMD with a deletion 13 in exon 50, and in a Ex50-MD Dog.

The present disclosure relates to a novel musculoskeletal stem cell (MSSC) differentiated from an ESC (embryonic stem cell) or an iPSC (induced pluripotent stem cell). The musculoskeletal stem cell of the present disclosure can be easily induced from a human embryonic stem cell or a human-derived pluripotent stem cell and can be effectively differentiated not only into bone but also into cartilage, tendon and muscle. Accordingly, it can be usefully used for prevention or treatment of various musculoskeletal diseases.

The present invention relates to compositions and methods utilizing hair follicle derived Non-Bulbar Dermal Sheath cells for use in the treatment or prevention of the tendon injuries.

The present disclosure relates to tissue engineering, and more particularly to a method for treating or repairing rotator cuff or other tendon tears or damage using scaffold-free 3-dimensional engineered tendon constructs.

The present invention relates to a construct for preventing immunological rejection when used in transplant, whether xenotransplant or allotransplant, which comprises: a) cells with regenerative capacity; b) collagen in 3-D gel state, or also called collagen 3-D matrix, obtained from pig's head cheeks; c) culture medium; d) an element aimed to be transplanted; and e) dry lyophilized spongy collagen molded with the shape of the element to be transplanted; It also relates to a method for producing collagen in a gel state in the form of dry lyophilized spongy mold and 3-D matrix.

Provided are enriched tissue extracts and methods of making and using such extracts. The enriched tissue extracts contain biologically active components. Some extracts produced by the methods contain extracellular vesicles. The methods can involve administering a physical stress on a biological sample comprising live cells or otherwise stimulating the live cells of the biological sample. Also contemplated are methods in which the biological sample does not contain live cells. The biological sample is incubated in an extraction solution for a period of time sufficient for extraction of biologically active components from the biological sample. Methods of using the extracts, or extracellular vesicles isolated therefrom, therapeutically and for in vitro purposes are also provided.

The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors. The invention further relates to compositions including a protease and a growth factor comprising a bone morphogenic protein (BMP) or a variant thereof. The invention also relates to methods of using the composition.

The invention relates to a method of producing a tendon neotissue from a population of adipose-derived stem cells (ASCs) subjected to mechanical and biological stimulations in a bioreactor system. The tendon neotissues are effective as implants to treat tendon or ligament injury in a subject. The invention also relates to a customized bioreactor useful for producing a tri-dimensional engineered tissue.

Methods for treating tendinopathy and tendonitis and for preventing tendinopathy are disclosed.